Can-Fite BioPharma (NYSE:CANF) Stock Price Down 3.1% – Should You Sell?

Can-Fite BioPharma Ltd. (NYSE:CANF) shares dropped 3.1% during trading on Tuesday . The stock traded as low as $0.3098 and last traded at $0.3170. Approximately 797,662 shares were traded during mid-day trading, a decline of 57% from the average daily volume of 1,857,222 shares. The stock had previously closed at $0.3270.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on CANF shares. Zacks Research upgraded shares of Can-Fite BioPharma to a “hold” rating in a research note on Thursday, November 6th. D. Boral Capital reaffirmed a “buy” rating and issued a $11.00 price target on shares of Can-Fite BioPharma in a report on Tuesday, November 18th. Finally, HC Wainwright reiterated a “buy” rating and set a $2.50 price objective on shares of Can-Fite BioPharma in a research note on Tuesday, November 4th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.75.

Can-Fite BioPharma Stock Performance

The stock has a market cap of $8.30 million, a PE ratio of -0.18 and a beta of 0.98. The company’s 50-day moving average price is $0.44 and its two-hundred day moving average price is $0.71.

Hedge Funds Weigh In On Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers lifted its position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 42.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 38,268 shares of the company’s stock after buying an additional 11,388 shares during the period. Rhumbline Advisers owned about 1.08% of Can-Fite BioPharma worth $57,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.